Experimental cancer drug begins first human testing
NCT ID NCT07434609
Summary
This is the first study in humans to test a new cancer drug called T320. The trial aims to find the safest dose and check for side effects in 150 patients with advanced solid tumors who have no effective standard treatments left. Patients will receive T320 injections every two weeks while researchers monitor how their bodies handle the drug and whether it shows any early signs of fighting their cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR (PHASE 1) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.